#Oncoalert

Dr. Kelly Shanahan

stage4kelly

#ASCO20 #bcsm @OncoAlert Let's talk for a sec about "tolerable" TRAEs. Every time I see a report with a laundry list of AEs like diarrhea, rash, myalgia, neutropenia, anemia, etc,

Nicole Kuderer

NicoleKuderer

@OncoAlert CCC19 in @Lancet: 30-day all-cause mortality was 13%, >2x the mortality of global average. Subgroups ranged from 0% mortality (ECOG=0 with no actively treated comorbidities) to 85% mortality (ECOG

Nicole Kuderer

NicoleKuderer

1/ Minimization of Toxicities: @oncology_bg so well said. Probably the most important language bias for our pts’ health is the incredible minimization of tox. If we misjudge the tox impact

Stephen V Liu

StephenVLiu

#ESMO20 Much anticipated results from CodeBreaK100: AMG 510 (sotorasib) in #KRAS G12C #NSCLC by @DavidHongMD building on exciting data seen over the past two years for this huge unmet need.

Ben Westphalen

BenWestphalen

LBA4 @ASCO #ASCO20 plenary session: Thierry Andre presents the results of KEYNOTE-177 (Pembro vs. CTX) in MSI/dMMR #crcsm : Doubling of PFS w. Prembro (. vs . months - HR

Mike Pishvaian

MPishvaian

1/@OncoAlert #ASCO2020 In addition to the outstanding GI abstracts, there will be many presentations and posters adding to the wealth of data that demonstrate that a real percentage of almost

Ibrahim Halil Sahin, MD

IbrahimSahinMD1

Pancreatic cancer stroma remains a dilemma for physicians scientist! In our study with @EileenMOReilly and Gokce Askan we identified that patients with dense stroma had lower cumulative local recurrence compared

Lobular Breast Cancer Alliance

LobularBCA

Is the #OncotypeDX recurrence score (RS) the best measure for #lobular #breastcancer? This retrospective analysis in @ACS_Research Journals suggests NO. 1/6 #bcsm @oncoalert @practiceupdate @medscape @elbcc @oesterreich @metzger https://acs

Fumiko Ladd Chino, MD

fumikochino

#Oncoalert: There are "large & persistent risk-adjusted differences in #cancer tx outcomes associated with the type of treating hospital... The quality of cancer care in the US is inconsistent &

Alex Shoushtari, MD

alexshoushtari

Five years ago today, I started my first patient on a Phase 1 study for #uvealmelanoma. Today, we learned that it improves survival over single agent checkpoint blockade. Thanks @Immunocore